Free Trial

VolitionRx Q3 2023 Earnings Report

VolitionRx logo
$0.63 -0.01 (-2.17%)
As of 01/17/2025 03:59 PM Eastern

VolitionRx EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.12
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

VolitionRx Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
$0.26 million
Beat/Miss
Missed by -$90.00 thousand
YoY Revenue Growth
N/A

VolitionRx Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

VolitionRx Earnings Headlines

VolitionRx's (VNRX) Buy Rating Reiterated at D. Boral Capital
Volition Issues Business Review 2024
Stunning Trump Exec Order Leaked
This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)...
See More VolitionRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VolitionRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VolitionRx and other key companies, straight to your email.

About VolitionRx

VolitionRx (NYSE:VNRX), a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

View VolitionRx Profile

More Earnings Resources from MarketBeat